Provincia di Macerata has published a tender for selling its shares in Acom spa (38,99%).

We enclosed tender documents  Allegato_1 Allegato_2 Allegato_3 Allegato_4

…CUPRYMINA…

What it is?

How it is used?

How does it work?

What benefit has it shown?

Other information about it

ACOM WILL BE GLAD TO MEET YOU IN OUR STAND NR 3

CASE REPORT: GLIOBLASTOMA IMAGING AND THERAPY WITH 64Cu-ASPARAGINE

C. Villano⁽¹⁾, G. Pigotti⁽²⁾, V. De Francesco⁽¹⁾, A. D. Di Nicola⁽¹⁾, G. Camplone⁽¹⁾, D. Martini⁽²⁾, E. Baldassarrini⁽²⁾, P. Panichelli⁽²⁾, G. Valentini⁽²⁾

⁽¹⁾ U.O.C. Medicina Nucleare Ospedale Civile “Spirito Santo”, Pescara, Italy

⁽²⁾ ACOM S.p.A., Montecosaro (MC), Località Cavallino, Italy

Glioblastoma is one of the most malignant and aggressive type of brain tumors with an average life expectance of less than 15 months. Our aim is to demostrate ⁶⁴Cu-asparagine capability to obtain both diagnosis and therapy in PET/CT imaging for a radiotargeted molecular therapy in patients with glioblastoma.

We introduced the new tracer asparagine radiolabeled with copper radionuclide according to following reasons: as showed in previous experimental data, glioblastoma needs asparagine for cellular metabolic activities and ⁶⁴Cu is able to link DNA and to destroy tumor cells thanks to its Auger effect. In fact, it is characterized by high Linear Energy Transfer (LET) in a small spatial region that can crash the cell. We report a particular case of a 71-year-old man with cerebral craniotomy (November, 2010) for a glioblastoma in the left rolandic region. In spite of surgery, the patient showed severe epilepsy with difficult gait (lower limb palsy) and non fluent speech with urinary incontinence. Moreover, he had not exact and real thought-movement nexus. He underwent a complete radiation therapy and a partial chemo treatment due to his pharmaceutical intolerance. Prior patient’s consent, ⁶⁴Cu-asparagine PET/CT has been evaluated in four different treatments, planned every 3 months. Two to 3 hours after 80 mCi dose injection, PET/CT acquisition was made according to cerebral protocol 15 min length with 128×128 matrix (Biograph 6 Truepoint PET/CT, Siemens). ⁶⁴Cu-asparagine scans showed a markedly volume reduction along all three sections (axial, coronal, sagittal): 1.42 cm, 2.6 cm and 1.5 cm. It’s also verified ⁶⁴Cu-asparagine capability to cross the blood-brain barrier (BBB) and to link cellular DNA. Patient’s life expectancy has been carried up to 15 months after tumor diagnosis with enhanced quality of life. Actually, the man is able to walk, to munch and swallow, to have a speech and his epilepsy crisis are shorter, milder and few and far between. These results are very promising but we need to extend this study to other patients to evaluate ⁶⁴Cu-asparagine real usefulness in glioblastoma diagnosis and therapy, mainly in pediatric population where it would be possible to obtain three-time greater efficacy.

An important achievement by our goup: 

Cuprymina - 925 MBq/ml - Precursore radiofarmaceutico, soluzioneflaconcino (vetro) – 1-3 ml- 1 flaconcino

Acom this year will be present at this important event too.

We await you in Birmingham for the 24 thEANM Congress (October 15-19,2011).

Acom’s stand is nr°. 35b

We are pleased to inform you that Acom Group will be in Rimini for the forthcoming X National AIMN Congress 2011.
We gladly invite you to visit us at our stand number  11.
In the extraordinary atmosphere, you can taste Italian wine and consult our professional assistance.
We guarantee an interesting meeting among science, medicine and flavor.

Acom has got the certificate to merchandise GLUCOMPET MONODOSE (FDG). In this historical moment of the nuclear medicine when legislative restrictions complicate distribution of radio pharmaceuticals. It gives a possibility for the hospital pharmacies, to sell radiopharmaceutical in a mono use vial. This is a solution that conjugates efficiency and economization for the public health. Acom will expand this logic also toward other radio pharmaceutical products.

We are pleased to inform you that Acom Group had a successfull  participation at the EANM 2010 congress in Vienna .

Acom Group

Jaipur, 3rd-6th December, 2009

Our Scientific Director, Dr. Gianluca Valentini, will take a spech at 41st Annual Conference of Society of Nuclear Medicine (India).

Acom Group

124I-βCIT is a new radiopharmaceutical compound for neurodegenerative disorder diagnosis with PET imaging. It is an analogue of cocaine and binds dopamine and serotonin transporters. Neurodegenerative disorders, such as Parkinson’s disease, are characterized by degeneration of dopaminergic neurons in the substantia nigra, with loss of their nerve terminals in the basal ganglia structure, especially in the striatum.

If you want try it in a clinical trial contact us by community. An interesting case report showed in reserved area, suggest a specific binding with melanoma brain metastasis.

If you want read it, please joint in to free Acom community

Acom Group